AnaptysBio Inc (ANAB) — Cash Flow-to-Debt Ratio
AnaptysBio Inc (ANAB) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-25.92 Million could theoretically repay 0% of its total liabilities ($316.94 Million) in one year. See AnaptysBio Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AnaptysBio Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for AnaptysBio Inc across 13 annual periods. For the full cash flow conversion analysis, see AnaptysBio Inc (ANAB) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for AnaptysBio Inc (2013–2025)
Year-by-year debt coverage analysis for AnaptysBio Inc. Check ANAB cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $19.70 Million | $327.19 Million | ▲ +118.4% |
| 2024 | -0.33x | $-135.34 Million | $412.97 Million | ▲ +1.2% |
| 2023 | -0.33x | $-120.80 Million | $364.29 Million | ▼ -56.9% |
| 2022 | -0.21x | $-73.59 Million | $348.28 Million | ▼ -31.9% |
| 2021 | -0.16x | $-45.92 Million | $286.64 Million | ▲ +77.6% |
| 2020 | -0.71x | $-14.16 Million | $19.82 Million | ▲ +69.0% |
| 2019 | -2.30x | $-69.52 Million | $30.19 Million | ▼ -7.4% |
| 2018 | -2.14x | $-48.51 Million | $22.63 Million | ▼ -140.2% |
| 2017 | -0.89x | $-19.44 Million | $21.78 Million | ▼ -126.4% |
| 2016 | -0.39x | $-9.03 Million | $22.91 Million | ▲ +43.2% |
| 2015 | -0.69x | $-9.67 Million | $13.94 Million | ▼ -190.6% |
| 2014 | 0.77x | $14.60 Million | $19.07 Million | ▲ +149.8% |
| 2013 | -1.54x | $-5.80 Million | $3.77 Million | — |